Italy-based Fidia Farmaceutici S.p.A announced that its Hyalubrix 60, a prefilled syringe with sodium hyaluronate solution for intra-articular injection, has successfully completed treatment in four patients at Hainan General Hospital’s Lecheng branch.
Product Profile
Hyalubrix 60 is designed to restore the viscoelastic properties of knee and hip synovial fluid. It serves as a temporary synovial fluid replacement for patients with degenerative or mechanical arthropathy affecting the hip and knee joints. The product works by binding to sodium hyaluronate receptor cell adhesion molecules and hyaluronic acid motor receptors, reducing the synthesis and release of interleukins, prostaglandin E2, matrix metalloproteinases, and free radicals. This leads to a decrease in inflammatory cells, reduced chondrocyte apoptosis, and promotes chondrocyte proliferation.
Clinical Trial Results
Clinical trials have demonstrated that Hyalubrix 60 can delay hip replacement in 82% of patients by four years. Compared to cross-linked sodium hyaluronate injections on the market, Hyalubrix 60 has no cross-linking agent residue or risk of sensitization and carcinogenicity. The incidence of adverse reactions is lower, requiring only 1-2 injections per year. The product offers high safety, good patient compliance, and significant clinical efficacy.-Fineline Info & Tech
